Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens
- PMID: 11463928
- PMCID: PMC1744325
- DOI: 10.1136/sti.77.4.276
Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens
Abstract
Objectives: To evaluate the cost effectiveness of a systematic screening programme for asymptomatic Chlamydia trachomatis infections in a female inner city population. To determine the sensitivity of the cost effectiveness analysis to variation in the probability of developing sequelae.
Methods: A decision tree was constructed to evaluate health effects of the programme, such as averted sequelae of chlamydial infection. Cost effectiveness from a societal perspective was estimated for screening by means of a ligase chain reaction on mailed, home obtained urine specimens, in a population with a C trachomatis test prevalence of 2.9%. An extensive sensitivity analysis was performed for the probability of sequelae, the percentage of preventable pelvic inflammatory disease (PID), and the discount rate.
Results: The estimated net cost of curing one woman, aged 15-40 years, of a C trachomatis infection is US$1210. To prevent one major outcome (PID, tubal factor infertility, ectopic pregnancy, chronic pelvic pain, or neonatal pneumonia), 479 women would have to be screened. The net cost of preventing one major outcome is $15 800. Changing the probability of PID after chlamydial infection from 5% to 25% decreases the net cost per major outcome averted from $28 300 to $6380, a reduction of 78%. Results were less sensitive to variations in estimates for other sequelae. The breakeven prevalence of the programme ranges from 6.4% for the scenario with all probabilities for complications set at the maximum value to a prevalence of 100% for probabilities set at the minimum value.
Conclusions: Systematic screening of all women aged 15-40 years for asymptomatic C trachomatis infections is not cost effective. Although the results of the analyses are sensitive to variation in the assumptions, the costs exceed the benefits, even in the most optimistic scenario.
Comment in
-
Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches.Sex Transm Infect. 2002 Feb;78(1):73-4. doi: 10.1136/sti.78.1.73. Sex Transm Infect. 2002. PMID: 11872873 Free PMC article. No abstract available.
-
Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing.Sex Transm Infect. 2002 Feb;78(1):74-5. doi: 10.1136/sti.78.1.74. Sex Transm Infect. 2002. PMID: 11872874 Free PMC article. No abstract available.
-
Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infection in women.Sex Transm Infect. 2002 Feb;78(1):76. doi: 10.1136/sti.78.1.76-a. Sex Transm Infect. 2002. PMID: 11872877 Free PMC article. No abstract available.
Similar articles
-
Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis.Value Health. 2001 May-Jun;4(3):266-75. doi: 10.1046/j.1524-4733.2001.43009.x. Value Health. 2001. PMID: 11705188
-
Chlamydia sequelae cost estimates used in current economic evaluations: does one-size-fit-all?Sex Transm Infect. 2017 Feb;93(1):18-24. doi: 10.1136/sextrans-2016-052597. Epub 2016 Jun 9. Sex Transm Infect. 2017. PMID: 27288417
-
Overestimation of complication rates in evaluations of Chlamydia trachomatis screening programmes--implications for cost-effectiveness analyses.Int J Epidemiol. 2004 Apr;33(2):416-25. doi: 10.1093/ije/dyh029. Int J Epidemiol. 2004. PMID: 15082651 Review.
-
Chlamydia trachomatis: impact on human reproduction.Hum Reprod Update. 1999 Sep-Oct;5(5):433-47. doi: 10.1093/humupd/5.5.433. Hum Reprod Update. 1999. PMID: 10582782 Review.
-
[Screening for asymptomatic Chlamydia trachomatis infection in pregnancy; cost-effectiveness favorable at a minimum prevalence rate of 3% or more].Ned Tijdschr Geneeskd. 2000 Dec 2;144(49):2350-4. Ned Tijdschr Geneeskd. 2000. PMID: 11129971 Dutch.
Cited by
-
Chlamydia trachomatis in female sex workers in Belgium: 1998-2003.Sex Transm Infect. 2005 Feb;81(1):89-90. doi: 10.1136/sti.2004.010272. Sex Transm Infect. 2005. PMID: 15681731 Free PMC article.
-
Screening for Sexually Transmitted Infections in Antenatal Care Is Especially Important Among HIV-Infected Women.Sex Transm Dis. 2015 Oct;42(10):566-8. doi: 10.1097/OLQ.0000000000000342. Sex Transm Dis. 2015. PMID: 26372928 Free PMC article. No abstract available.
-
Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling.Sex Transm Infect. 2006 Jun;82(3):193-200; discussion 201. doi: 10.1136/sti.2005.017517. Sex Transm Infect. 2006. PMID: 16731666 Free PMC article.
-
Cost-effectiveness of screening strategies for Chlamydia trachomatis using cervical swabs, urine, and self-obtained vaginal swabs in a sexually transmitted disease clinic setting.Sex Transm Dis. 2008 Jul;35(7):649-55. doi: 10.1097/OLQ.0b013e31816ddb9a. Sex Transm Dis. 2008. PMID: 18461013 Free PMC article.
-
Evaluation of Chlamydia trachomatis screening from the perspective of health economics: a systematic review.Front Public Health. 2023 Oct 10;11:1212890. doi: 10.3389/fpubh.2023.1212890. eCollection 2023. Front Public Health. 2023. PMID: 37881345 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical